A5079841694- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Gout, Hyperuricemia, Uric Acid
- Autoimmune and Inflammatory Disorders Research
- Spondyloarthritis Studies and Treatments
- Total Knee Arthroplasty Outcomes
- Orthopaedic implants and arthroplasty
- Psoriasis: Treatment and Pathogenesis
- Urticaria and Related Conditions
- Hepatitis C virus research
- Case Reports on Hematomas
- Pharmaceutical Practices and Patient Outcomes
- Monoclonal and Polyclonal Antibodies Research
- Systemic Sclerosis and Related Diseases
- Patient Safety and Medication Errors
- Osteoarthritis Treatment and Mechanisms
- Biosimilars and Bioanalytical Methods
- Pharmaceutical studies and practices
- Health Systems, Economic Evaluations, Quality of Life
- Medication Adherence and Compliance
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Hip and Femur Fractures
- Pharmacovigilance and Adverse Drug Reactions
University of Massachusetts Chan Medical School
2015-2024
Navitas Systems (United States)
2021-2024
Yale University
2020-2022
Carnegie Mellon University
2022
Berkshire Medical Center
2022
University of North Carolina at Chapel Hill
2022
University of Alabama at Birmingham
2022
Global Healthy Living Foundation
2022
Columbia University
2020
Albany Medical Center Hospital
2015-2020
<h3>Context</h3> Adverse drug events, especially those that may be preventable, are among the most serious concerns about medication use in older persons cared for ambulatory clinical setting. <h3>Objective</h3> To assess incidence and preventability of adverse events <h3>Design, Setting, Patients</h3> Cohort study all Medicare enrollees (30 397 person-years observation) by a multispecialty group practice during 12-month period (July 1, 1999, through June 30, 2000), which possible...
To provide guidance for the management of gout, including indications and optimal use urate-lowering therapy (ULT), treatment gout flares, lifestyle other medication recommendations.Fifty-seven population, intervention, comparator, outcomes questions were developed, followed by a systematic literature review, network meta-analyses with ratings available evidence according to Grading Recommendations Assessment, Development Evaluation (GRADE) methodology, patient input. A group consensus...
Objective To provide guidance for the management of gout, including indications and optimal use urate‐lowering therapy ( ULT ), treatment gout flares, lifestyle other medication recommendations. Methods Fifty‐seven population, intervention, comparator, outcomes questions were developed, followed by a systematic literature review, network meta‐analyses with ratings available evidence according to Grading Recommendations Assessment, Development Evaluation GRADE ) methodology, patient input. A...
Use of several immunomodulatory agents has been associated with reduced numbers cardiovascular (CV) events in epidemiologic studies rheumatoid arthritis (RA). However, it is unknown whether time-averaged disease activity RA correlates CV events.We studied patients whose cases were followed a longitudinal US-based registry. Time-averaged was assessed during followup using the area under curve Clinical Disease Activity Index (CDAI), validated measure activity. Age, sex, presence diabetes...
Objectives: To gather information on patient‐level factors associated with risk of adverse drug events (ADEs) that may allow focus prevention efforts patients at high risk. Design: Nested case‐control study. Setting: Large multispecialty group practice in New England. Participants: All Medicare enrollees cared for by a during 1 year (N=30,397 person‐years from July 1, 1999, through June 30, 2000). For each patient an ADE, control was randomly selected. Measurements: Data were abstracted...
Adherence to urate-lowering drugs (ULDs) has not been well evaluated among those with gout. Our aim was assess the level and determinants of non-adherence ULDs prescribed for We identified persons using two integrated delivery systems aged 18 years or older a diagnosis gout who initiated use allopurinol, probenecid sulfinpyrazone from 1 January 2000 30 June 2006. Non-adherence measured medication possession ratio (MPR) over first year therapy defined as an MPR < 0.8. Descriptive statistics...
<h3>Purpose</h3> To compare the effectiveness of anti-tumour necrosis factor (TNF) agents in biologically naive and 'switched' rheumatoid arthritis (RA) patients. <h3>Methods</h3> RA patients enrolled CORRONA registry newly prescribed adalimumab (n=874), etanercept (n=640), or infliximab (n=728) were stratified based on previous anti-TNF use. Clinical at 6, 12 24 months was examined using modified American College Rheumatology response criteria (mACR20/50/70) achievement remission (28-joint...
Objectives To characterize adverse drug events ( ADE s) occurring within the high‐risk 45‐day period after hospitalization in older adults. Design Clinical pharmacists reviewed ambulatory records of 1,000 consecutive discharges. Setting A large multispecialty group practice closely aligned with a M assachusetts‐based health plan. Participants Hospitalized individuals aged 65 and discharged home. Measurements Possible drug‐related incidents during were identified presented to pair...
<h3>Objective</h3> There is a lack of standardisation in the terminology used to describe gout. The aim this project was develop consensus statement describing recommended nomenclature for disease states <h3>Methods</h3> A content analysis gout-related articles from rheumatology and general internal medicine journals published over 5-year period identified potential labels commonly assigned them. Based on these findings, experts gout were invited participate Delphi exercise face-to-face...
Objective The language currently used to describe gout lacks standardization. aim of this project was develop a consensus statement on the labels and definitions basic disease elements gout. Methods Experts in (n = 130) were invited participate Delphi exercise face‐to‐face meeting reach labeling for Disease current use derived from content analysis contemporary medical literature, results item selection meeting. Results There 51 respondents 30 attendees at Consensus agreement (≥80%) achieved...
<h3>Introduction</h3> Chronic kidney disease (CKD) is a common comorbidity of rheumatoid arthritis (RA). The association longitudinal RA activity with long-term function has remained uncertain. <h3>Method</h3> We analysed multicentre prospective registry in the USA from 2001 to 2022. exposure was updated time-averaged Clinical Disease Activity Index (TA-CDAI) categories study enrolment. primary outcome estimated glomerular filtration rate (eGFR) change. Secondary outcomes included...
Little is known about the characteristics, evaluation and treatment of women with gout.To examine epidemiological differences in between men a large patient population.The data from approximately 1.4 million people who were members seven managed care plans USA for at least 1 year January 1999 31 December 2003 examined. Adult had pharmacy benefits two ambulatory claims specifying diagnosis gout identified. In addition, new users urate-lowering drugs (ULDs) identified to assess adherence...
Objectives: We sought to examine patients’ and providers’ views on the treatment of gout better understand why management is suboptimal. Methods: In-depth telephone interviews were conducted with patients (n = 26) who initiated a urate-lowering drug (ULD) in previous 6 months providers care for 15). The audiotaped transcribed verbatim. Using qualitative methods, results analysed themes identified. Interviews focused acute management, chronic prevention improvement strategies. Results:...
OBJECTIVES: To evaluate the efficacy of computerized provider order entry with clinical decision support for preventing adverse drug events in long‐term care. DESIGN: Cluster‐randomized controlled trial. SETTING: Two large care facilities. PATIENTS: One thousand one hundred eighteen residents 29 resident units. INTERVENTION: The units, each entry, were randomized to having a system (intervention units) or not (control units). MEASUREMENTS: number events, severity and whether preventable....
ABSTRACT Background Few population‐based studies have reported the prevalence of psoriatic disease. Objective We validated computerized diagnoses to estimate psoriasis and arthritis. Method identified adults with ≥1 ICD‐9 diagnosis codes 696.0 (psoriatic arthritis) or 696.1 (psoriasis) in clinical encounter data during 1996–2009 used chart review confirm random samples patients. then best performing case‐finding algorithms point Results The number persons a for (ICD‐9 code 696.1) was 87 827....